Fig. 6From: Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settingsForest plot of arm-level sensitivity analysis. The box size is based on the precision of Spearman’s rhoBack to article page